Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Chemotherapy
Higher cycle of epidoxorubicin/docetaxel increased pathological response rates
November 10th, 2005
Administering 6 cycles of epidoxorubicin/docetaxel increased pathological complete response (pCR) rates over 3 cycles. "We conducted a prospective randomized study to compare the results of 3 cycles of epidoxorubicin/docetaxel to 6 cycles of epidoxorubicin/docetaxel prior to surgery in breast cancer patients with clinical stages II and III. Forty-five patients eligible for neoadjuvant chemotherapy were randomly assigned to receive either 3 (Group 1) or 6 (Group 2) cycles of epidoxorubicin/docetaxel prior to surgery," scientists writing in the journal Anti-Cancer Drugs reported. "Chemotherapy consisted of epidoxorubicin 75 mg/m2 and...
Source: Women's Health Weekly (2005-11-10)
|
